902 related articles for article (PubMed ID: 24382354)
1. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.
Ichikawa Y; Ghanefar M; Bayeva M; Wu R; Khechaduri A; Naga Prasad SV; Mutharasan RK; Naik TJ; Ardehali H
J Clin Invest; 2014 Feb; 124(2):617-30. PubMed ID: 24382354
[TBL] [Abstract][Full Text] [Related]
2. Elevated mitochondrial iron triggers doxorubicin-mediated cardiomyopathy.
Cancer Discov; 2014 Mar; 4(3):OF9. PubMed ID: 24596224
[TBL] [Abstract][Full Text] [Related]
3. Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export.
Ichikawa Y; Bayeva M; Ghanefar M; Potini V; Sun L; Mutharasan RK; Wu R; Khechaduri A; Jairaj Naik T; Ardehali H
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4152-7. PubMed ID: 22375032
[TBL] [Abstract][Full Text] [Related]
4. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
Hasinoff BB; Patel D; Wu X
Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
[TBL] [Abstract][Full Text] [Related]
5. Ferritin heavy chain as main mediator of preventive effect of metformin against mitochondrial damage induced by doxorubicin in cardiomyocytes.
Asensio-Lopez MC; Sanchez-Mas J; Pascual-Figal DA; de Torre C; Valdes M; Lax A
Free Radic Biol Med; 2014 Feb; 67():19-29. PubMed ID: 24231192
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
7. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
Hasinoff BB; Patel D; Wu X
Cardiovasc Toxicol; 2020 Jun; 20(3):312-320. PubMed ID: 31773441
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
9. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
[TBL] [Abstract][Full Text] [Related]
10. ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity.
Belmonte F; Das S; Sysa-Shah P; Sivakumaran V; Stanley B; Guo X; Paolocci N; Aon MA; Nagane M; Kuppusamy P; Steenbergen C; Gabrielson K
Am J Physiol Heart Circ Physiol; 2015 Oct; 309(8):H1271-80. PubMed ID: 26254336
[TBL] [Abstract][Full Text] [Related]
11. Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice.
Pillai VB; Bindu S; Sharp W; Fang YH; Kim G; Gupta M; Samant S; Gupta MP
Am J Physiol Heart Circ Physiol; 2016 Apr; 310(8):H962-72. PubMed ID: 26873966
[TBL] [Abstract][Full Text] [Related]
12. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
Damiani RM; Moura DJ; Viau CM; Caceres RA; Henriques JAP; Saffi J
Arch Toxicol; 2016 Sep; 90(9):2063-2076. PubMed ID: 27342245
[TBL] [Abstract][Full Text] [Related]
13. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
[TBL] [Abstract][Full Text] [Related]
14. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
[TBL] [Abstract][Full Text] [Related]
16. Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice.
Pillai VB; Kanwal A; Fang YH; Sharp WW; Samant S; Arbiser J; Gupta MP
Oncotarget; 2017 May; 8(21):34082-34098. PubMed ID: 28423723
[TBL] [Abstract][Full Text] [Related]
17. The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity.
Russo M; Guida F; Paparo L; Trinchese G; Aitoro R; Avagliano C; Fiordelisi A; Napolitano F; Mercurio V; Sala V; Li M; Sorriento D; Ciccarelli M; Ghigo A; Hirsch E; Bianco R; Iaccarino G; Abete P; Bonaduce D; Calignano A; Berni Canani R; Tocchetti CG
Eur J Heart Fail; 2019 Apr; 21(4):519-528. PubMed ID: 30843309
[TBL] [Abstract][Full Text] [Related]
18. Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.
Liu Y; Asnani A; Zou L; Bentley VL; Yu M; Wang Y; Dellaire G; Sarkar KS; Dai M; Chen HH; Sosnovik DE; Shin JT; Haber DA; Berman JN; Chao W; Peterson RT
Sci Transl Med; 2014 Dec; 6(266):266ra170. PubMed ID: 25504881
[TBL] [Abstract][Full Text] [Related]
19. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
[TBL] [Abstract][Full Text] [Related]
20. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
